Status:
COMPLETED
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
Lead Sponsor:
Syndax Pharmaceuticals
Conditions:
Breast Cancer
Estrogen Receptor-Positive Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
Eligibility Criteria
Inclusion
- Postmenopausal female patients
- Histologically or cytologically confirmed estrogen receptor positive (ER+) breast cancer
- Relapsed or progressed on prior treatment with aromatase inhibitor (AI)
- Metastatic disease must be measurable
- Patients receiving palliative radiation at the non-target lesions must have a 2 week wash out period following completion of the treatment prior to enrollment
- Patient may have had one prior chemotherapy as part of first line therapy as long as it was received before initiation of prior AI
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 1
- Laboratory parameters: a)Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100.0 x 10\^9/L; Absolute Neutrophil Count (ANC ≥) 1.5 x 10\^9/L without the use of hematopoietic growth factors b)Creatinine less than 2.5 times the upper limit of normal for the institution c)Aspartate transaminase (AST) and alanine transaminase (ALT) less than 2.5 times the upper limit of normal for the institution
- Able to understand and give written informed consent and comply with study procedures
Exclusion
- Relapse on treatment with non-steroidal AI after less than 12 months for patients in the adjuvant setting
- Progressive disease after less than 3 months treatment with most recent AI for patients with metastatic disease
- Rapidly progressive, life-threatening metastases
- Any palliative radiotherapy to the measurable lesion
- Previous treatment with SNDX-275 or any other histone deacetylase (HDAC) inhibitor including valproic acid
- Allergy to benzamides or inactive components of the study drug
- A history of allergies to any active or inactive ingredients of exemestane
- Any concomitant medical condition that precludes adequate study treatment compliance
- Patient is currently enrolled in (or completed within 30 days before study drug administration) another investigational drug study
- Patient is currently receiving treatment with valproic acid, Zolinza (vorinostat) or any other HDAC inhibitor or deoxyribonucleic acid (DNA) methyltransferase inhibitor or any systemic anticancer treatment (with the exception of Lupron)
Key Trial Info
Start Date :
June 13 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 26 2012
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00676663
Start Date
June 13 2008
End Date
November 26 2012
Last Update
May 11 2022
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
California Cancer Care
Greenbrae, California, United States
2
Moores UCSD Cancer Center
La Jolla, California, United States
3
Scripps Health
La Jolla, California, United States
4
University of Colorado
Aurora, Colorado, United States